In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Mass screening for atrial fibrillation using n-terminal pro b-type natriuretic peptide - preliminary results from the strokestop 2 study

Session Atrial fibrillation - Detection, treatment, outcomes

Speaker Doctor Katrin Kemp Gudmundsdottir

Event : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Epidemiology, Prognosis, Outcome
  • Session type : Rapid Fire Abstracts

Authors : K Kemp Gudmundsdottir (Stockholm,SE), E Svennberg (Stockholm,SE), F Al-Khalili (Stockholm,SE), T Fredriksson (Stockholm,SE), V Frykman (Stockholm,SE), L Friberg (Stockholm,SE), M Rosenqvist (Stockholm,SE), J Engdahl (Stockholm,SE)

K. Kemp Gudmundsdottir1 , E. Svennberg1 , F. Al-Khalili1 , T. Fredriksson1 , V. Frykman1 , L. Friberg2 , M. Rosenqvist1 , J. Engdahl1 , 1Danderyd University Hospital - Stockholm - Sweden , 2Karolinska Institute - Stockholm - Sweden ,

Atrial Fibrillation - Epidemiology, Prognosis, Outcome

European Heart Journal ( 2018 ) 39 ( Supplement ), 264

Background: Atrial fibrillation (AF) is common among the elderly and a significant risk-factor for embolic ischemic stroke. AF is often asymptomatic and therefore undiagnosed. We have previously reported a yield of 3% of newly diagnosed AF using intermittent ECG screening in a 75-year-old population. N-terminal pro b-type natriuretic peptide (NT-proBNP) levels are elevated in patients with AF, and prior studies indicate that NT-proBNP elevation can predict development of AF. In patients with known AF, NT-proBNP levels seem to be in proportion to stroke risk.

Purpose: We aim at reporting preliminary data on the yield of systematic screening for AF in a 75/76-year-old population using NT-proBNP and handheld ECG recordings in a stepwise screening procedure.

Methods: All individuals born in 1940 and 1941 residing in the Stockholm region (n=28,712) were randomised in a 1:1 fashion to be invited to a screening program for AF or to serve as a control group. Participants free of AF (n=6127) had NT-proBNP analysed. Individuals with NT-proBNP ≥125 ng/L (n=3636, 59%) were offered extended ECG-screening whereas individuals with NT-proBNP <125 ng/L (n=2491, 41%) had a single one-lead ECG recording.

Results: In participants with NT-proBNP ≥125 ng/L 169 (4,6%, 95% CI 4.0–5.4) were diagnosed with AF, of these 32 (24%) were diagnosed on their first ECG recording. One participant with NT-proBNP <125ng/L was diagnosed with AF on a single-lead ECG. Oral anticoagulation (OAC) treatment was initiated in 93% of those with new AF. In the population randomized to screening OAC treatment was commenced in 1% (158/13845).

Conclusions: NT-proBNP-enriched systematic screening for AF identified a significant proportion of participants with untreated AF. Oral anticoagulation treatment was highly accepted in the group diagnosed with AF.

AF detection

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are